SABCS 2021

Conference Coverage

Phase 3 Studies Herald More Options for Metastatic Breast Cancer

By

Alan P. Lyss, MD

Dr Alan Lyss details the results and clinical implications of the EMERALD, PHOEBE, and DESTINY-Breast03 trials.

BRCA2 Linked to Inferior Outcomes of Treatment With CDK4/6 Inhibitors Plus Endocrine Therapy

By

Leah Lawrence

Patients with germline BRCA2 mutations had relatively worse outcomes with endocrine therapy and CDK4/6 inhibitors in the first-line setting and all lines of therapy.

Surgical Staging Affects Some QOL Scores in Early Breast Cancer

By

Andrea S. Blevins Primeau, PhD, MBA

An analysis of patients in the INSEMA trial sought to determine the impact of no SLNB vs SLNB and SLNB alone vs SLNB with ALND on quality of life for patients with breast cancer.

Breast Cancer-Related Lymphedema More Common Among Black Women

By

Leah Lawrence

A prospective study sought to determine the significance of race on the risk of developing lymphedema and disease severity in women with breast cancer.

Samuraciclib Plus Fulvestrant Demonstrates Antitumor Activity in Advanced Breast Cancer

By

Andrea S. Blevins Primeau, PhD, MBA

A single-arm cohort study sought to determine the efficacy of adding samuraciclib to treatment for ER-positive and/or PGR-positive, HER2-negative breast cancer.

ctDNA Promising Biomarker in Ribociclib, Letrozole-Treated HR+/HER2- Advanced Breast Cancer

By

Leah Lawrence

Liquid biopsies were used to determine whether ctDNA analysis was predictive of disease progression in women with HR+/HER2- breast cancer.

Monitoring ESR1 Mutations May Optimize Treatment in Metastatic Breast Cancer

By

Andrea S. Blevins Primeau, PhD, MBA

Monitoring circulating mutated ESR1 enabled optimization of the endocrine therapy used with a CDK4/6 inhibitor.

Trastuzumab Deruxtecan Improved PFS Across HER2+ Breast Cancer Subgroups

By

Leah Lawrence

Researchers presented updated findings from the DESTINY-Breast03 trial.

Elacestrant Improved PFS in Metastatic Breast Cancer Progressing on CDK4/6 Therapy

By

Leah Lawrence

Elacestrant showed a statistically significant and clinically meaningful progression-free survival improvement compared with standard of care.

First-Line Ribociclib/Letrozole Effective in Breast Cancer Across Subgroups

By

Andrea S. Blevins Primeau, PhD, MBA

An analysis of a cohort of patients from the MONALEESA-2 trial sought to determine the efficacy of adding ribociclib to letrozole for HR+/HER2- breast cancer.

Increasing Marker Clip Placement During Ultrasound-Guided Breast Biopsy

By

Andrea S. Blevins Primeau, PhD, MBA

The delay in clip placement was associated with significant anxiety among the patients who were interviewed.

Recurrence Risk Reduced With AI vs Tamoxifen in Premenopausal ER+ Breast Cancer

By

Leah Lawrence

This meta-analysis was conducted on data from 4 clinical trials including more than 7000 women with ER+ breast cancer.

Genomic-Based Targeted Therapy Improved PFS for Certain Metastatic Breast Cancers

By

Leah Lawrence

The researchers found that targeted therapies matched to genomic alterations in ESCAT tier I/II significantly improved progression-free survival.

Final Analysis of PALLAS Shows No Benefit With Palbociclib Plus Endocrine Therapy in Early Breast Cancer

By

Andrea S. Blevins Primeau, PhD, MBA

Palbociclib added to adjuvant endocrine therapy failed to improve iDFS.

Outcomes in Inflammatory Breast Cancer Improved With Modern Treatment

By

Andrea S. Blevins Primeau, PhD, MBA

Researchers evaluated outcomes for patients with breast cancer who were treated with a modern approach compared with a historical standard approach.

KEYNOTE-355 Identifies PD-L1 Expression Cutoff for Pembrolizumab Benefit in mTNBC

By

Leah Lawrence

A subgroup analysis of the KEYNOTE-355 trial sought to determine which patients with metastatic TNBC would benefit from treatment with pembrolizumab and chemotherapy.